CleaRank Financial AI • AI-powered analysis using real-time market data from TwelveData
Analysis reviewed by Michelle Sofia, Market Analyst. Data refreshed daily. Not financial advice.
Edwards Lifesciences Corporation (EW) is currently trading at $86.47, positioned above its 20-day EMA and 200-day SMA, but below its 50-day SMA. The company operates within the Healthcare sector, specifically in Medical Devices, a field characterized by innovation and regulatory oversight. Analysts maintain a strong 'Buy' consensus, with 29 covering analysts setting a median price target of $102.50, implying an 18.5% upside from current levels. This positive outlook is supported by projected revenue growth of 11.00% for the current year and 10.00% for the next, alongside an expected earnings per share of $3.00 for the current year. Despite the positive analyst sentiment, insider activity shows a 'Moderate Sell Signal' with $32.6 million in total sales versus no reported purchases. This warrants attention, though it is important to note that the insider narrative indicates these are primarily officer sales, not necessarily a reflection of fundamental weakness. The company's financial health appears solid, with a healthy profit margin of 15.43% and a low debt-to-equity ratio of 0.07, comparing favorably to sector averages. The primary risk revolves around the moderate insider selling and the stock's current positioning relative to its 50-day moving average.
EW at a glance
Edwards Lifesciences Corporation (EW): Buy, 74/100 on CleaRank's AI score.
TrendMixed: the price is above its 200-day but below its 50-day moving average ($85.13 and $88.49).
EarningsEW beat estimates in 2 of its last 3 quarters, yet fell the next day after 1 of those beats.
InsidersInsiders sold $32.6M and made no open-market purchases over the last 18 months.
ValuationP/E of 52.0 against 31.9 for the Healthcare sector: a premium to peers (+63%).
As of October 14, 2026, Edwards Lifesciences Corporation (EW) trades at $86.47. Wall Street's consensus target is $102.50 across 29 analysts. The 14-day RSI (daily closes) is 49, in neutral territory, and the price is below its 50-day simple moving average of $88.49.
Figures as of October 14, 2026.
Only on CleaRank
Figures we compute ourselves from EW's own price, earnings and insider-filing history. Tap one to see it in context.
Trading at a significant premium to sector peers (+63%), suggesting market expectations for superior growth or market position.
EW Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
In the last 3 quarters, EW beat the analyst estimate 2 times; the stock fell in the first session after 1 of those beats.
EW earnings surprises and the stock's reaction
Report
EPS estimate
EPS actual
Surprise
First session
5 sessions
Jul 23, 2026
$0.74
$0.78
+5.41%
-1.42%
+3.70%
Apr 23, 2026
$0.73
$0.78
+6.85%
+5.56%
+4.74%
Feb 10, 2026
$0.62
$0.58
-6.45%
+2.96%
+2.50%
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
As of October 14, 2026, EW has beaten the analyst EPS estimate in 2 of its last 3 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 23, 2026, came in 5.41% above the estimate and the stock moved -1.42% in the first session.
EW Analysis
Company's Health4/5
12-Month Analyst Target+18.54% above price
Median of 29 analysts (12-month)
$102.50
AI Analyst Consensus ScoreBuy
The 14-day RSI is at 48.92, indicating neutral momentum. The MACD is currently at -0.67, suggesting a slight bearish short-term trend. Key support levels are found at the 20-day EMA ($86.44) and the 200-day SMA ($85.13). Resistance is noted at the 50-day SMA ($88.49). The overall chart structure suggests a period of consolidation, with the stock testing key moving averages.
ProTips
The stock is trading below its 50-day SMA, suggesting potential near-term headwinds. Consider waiting for a confirmed break above this level for stronger bullish confirmation.
Key Catalysts
BullishPositive Analyst Ratings and Price Target Increases
Multiple recent analyst upgrades and reiterations of 'Buy' or 'Overweight' ratings, coupled with a median price target of $102.50, indicate strong institutional conviction in EW's future performance.
Source: Wall Street Analyst Reports
BearishModerate Insider Selling Signal
Insiders have sold $32.6 million in stock with no reported purchases, signaling a 'Moderate Sell Signal' which warrants investor attention.
Source: Insider Transaction Data
NeutralTrading Below 50-Day SMA
The stock is currently trading below its 50-day simple moving average of $88.49, which may act as resistance and indicate potential short-term weakness.
Source: Technical Analysis Data
Market Outlook
The base case scenario for Edwards Lifesciences Corporation (EW) anticipates continued growth, driven by strong analyst estimates and a solid fundamental profile. The company's strong profit margins and low debt provide a stable foundation for achieving projected revenue growth of 11.00% this year and 10.00% next year. Potential catalysts for upside include successful product launches or positive clinical trial outcomes, which could further strengthen investor confidence and drive the stock towards its higher analyst targets. Conversely, any significant insider selling beyond current levels, increased competitive pressures, or adverse regulatory developments could pose downside risks, potentially pushing the stock back towards its support levels around the 200-day SMA of $85.13.
Key Statistics
Market Cap
49.84B
P/E Ratio
52.04
EPS (TTM)
1.66
Dividend Yield
0.00%
52 Week High
96.29
52 Week Low
72.42
As of October 14, 2026, EW trades at $86.47, with a market value of $49.84B and a P/E ratio of 52.04.
Edwards Lifesciences Corporation (EW) exhibits a price-to-sales ratio of 7.65, which is higher than the sector median of 3.7, suggesting a premium valuation relative to its revenue. However, its profit margin of 15.43% and return on equity of 9.18% are strong, outperforming the sector median ROE of 6.9%. The company's debt-to-equity ratio stands at a very low 0.07, indicating a strong balance sheet and minimal financial risk compared to the sector average. While the price-to-sales ratio suggests a potential valuation stretch, the company's profitability and low leverage provide a solid fundamental underpinning. Analysts project revenue growth of 11.00% for the current year and 10.00% for the next, indicating continued expansion. The current P/E ratio of 52.04 is elevated, but this should be viewed in the context of its strong growth estimates and profitability.
Earnings & Growth Analysis
Edwards Lifesciences Corporation (EW) most recently reported earnings on July 23, 2026, with an actual EPS of $0.78, beating the estimate of $0.74 by 5.41%, though the stock saw a 1.42% decline on the news. Prior to that, the company beat estimates by 6.85% on April 23, 2026, with the stock rising 5.56%. The company has a mixed recent earnings history, missing estimates by 6.45% in February 2026. Analysts forecast current quarter EPS at $0.73695 and next year's EPS at $3.38, reflecting continued earnings growth.
Key Risks
The primary risks for Edwards Lifesciences Corporation (EW) include the moderate insider selling signal, with $32.6 million in sales reported, and the stock trading below its 50-day moving average, indicating potential short-term weakness. Competition within the medical device sector is intense, and regulatory changes could impact product approvals and market access. Also, any slowdown in projected revenue or earnings growth could pressure the stock's premium valuation.
Technical Indicators i
RSI (14-day)
48.92
MACD (12, 26)
-0.675
SMA (50-day)
88.49
SMA (200-day)
85.13
Technical RatingBearish
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($88.49) above the 200-day SMA ($85.13), price is trading below the 50-day SMA.
As of October 14, 2026, with EW at $86.47, its 14-day RSI is 48.9 (neutral territory), its 50-day simple moving average is $88.49 and its 200-day is $85.13.
Calculated by CleaRank on daily closes as of October 14, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)+0.35
Weak correlation
Nasdaq 100 (QQQ)+0.30
Weak correlation
Bitcoin (BTC)+0.08
Weak correlation
Gold (XAU)+0.01
Weak correlation
As of October 14, 2026, EW's 1-year correlation of daily returns is +0.35 with S&P 500 (SPY), +0.30 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and +0.01 with gold (XAU).
Check Custom Correlation
How does any other asset move with EW? One year of daily closes, Pearson correlation.
Try
EW Wall Street View
12-month price targets
Low $84.00Median $102.50 (+18.5%)High $110.00
Ratings
Buy 23Hold 6Sell 03 months ago: 22 of 29 buy
Recent rating actions
Recent analyst rating actions on EW
Date
Firm
Action
Rating
Oct 7, 2026
Barclays
Initiates
Overweight
Sep 11, 2026
BTIG
Reiterates
Buy
Jul 28, 2026
UBS
Assumes
Buy
Jul 25, 2026
Leerink Partners
Upgrade
Outperform
Jul 24, 2026
Leerink Partners
Upgrade
Outperform
Jul 24, 2026
JP Morgan
Maintains
Overweight
As of October 14, 2026, 29 Wall Street analysts cover EW: 23 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $84.00 to $110.00, with a median of $102.50, 18.5% above the price of $86.47.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
EW Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative2%Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$84.74
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$86.47
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$82.16
MAX LOSS
-3.1%
Volatility-Adjusted Stop Loss
Calculated based on RSI (48.9) and current market volatility
These levels come from EW's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Growth of $10,000
A $10,000 investment in EW in October 2016 would be worth about $22,053 today, compared with about $36,506 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
EW Drawdowns & Recovery
Worst fall, last 10 years
-54.3%
December 2021 to July 2024
Recovery
Not yet
still 33.8% below the December 2021 peak
From the 10-year high
-33.8%
highest close, December 2021
1-year holds that gained
70%
of every 1-year window
As of October 14, 2026, EW's worst peak-to-trough fall over the last 10 years was -54.3% (December 2021 to July 2024); it is still 33.8% below that peak, and 70% of 1-year holding periods ended with a gain.
From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in EW today could grow to about $19,846 by 2036 in the base case, with a 90th-percentile outcome near $75,920 and a 10th-percentile outcome around $5,188. Projections are statistical simulations, not guarantees.
EW Stock Price Prediction: 2030
CleaRank's simulation projects a price near $114 for EW by 2030 in the base case, from $86.47 today (1.3x over 4 years). The 10th-percentile path ends near $48.69. These are outcomes of a Monte Carlo simulation run on EW's historical return distribution, not price targets, and they assume no dividends are reinvested.
EW simulated price paths by year
Year
10th percentile
Base case
90th percentile
2027
$60.59
$92.60
$142
2028
$54.43
$99.17
$181
2029
$50.93
$106
$221
2030
$48.69
$114
$266
2031
$47.17
$122
$315
Method: a lognormal simulation of EW's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
As of October 14, 2026, EW insiders reported 52 open-market sales worth $32.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
Recent insider transactions in EW
Date
Insider
Type
Shares
Value
Oct 8, 2026
LIPPIS DANIEL J
Officer
Sell
619
$53.0K
Oct 8, 2026
LIPPIS DANIEL J
Officer
Option
619
$45.0K
Sep 11, 2026
LIPPIS DANIEL J
Officer
Sell
619
$54.2K
Sep 11, 2026
LIPPIS DANIEL J
Officer
Option
619
$45.0K
Aug 31, 2026
DAHL ANDREW M
Officer
Sell
544
$49.5K
Aug 28, 2026
BRULS ANNETTE
Officer
Sell
2.6K
$237.9K
Aug 26, 2026
CHOPRA DAVEEN
Officer
Sell
31.8K
$2.9M
Aug 26, 2026
MARKOWITZ WAYNE
Officer
Sell
1.2K
$113.4K
Aug 26, 2026
CHOPRA DAVEEN
Officer
Option
31.8K
$2.3M
Aug 11, 2026
LIPPIS DANIEL J
Officer
Sell
619
$57.0K
Page 1 of 1
Frequently Asked Questions
What is the outlook for Edwards Lifesciences Corporation (EW) stock over the next 6-12 months?
The outlook for Edwards Lifesciences Corporation (EW) is cautiously optimistic, with analysts maintaining a 'Buy' rating and a median price target of $102.50. The company is expected to continue its revenue growth trajectory, supported by strong earnings estimates. Key catalysts could include positive clinical trial results or new product approvals, while risks include increased competition and potential regulatory hurdles.
What are the biggest risks facing Edwards Lifesciences Corporation (EW)?
The main risks for Edwards Lifesciences Corporation (EW) include moderate insider selling totaling $32.6 million, the stock trading below its 50-day moving average, and intense competition within the medical device sector. Regulatory changes and any deceleration in projected growth could also negatively impact the stock.
How does Edwards Lifesciences Corporation (EW) compare to its sector averages?
Edwards Lifesciences Corporation (EW) shows a higher price-to-sales ratio (7.65) compared to the Healthcare sector median (3.7). However, its profit margin (15.43%) and return on equity (9.18%) are strong, outperforming the sector median ROE (6.9%). The company also boasts a very low debt-to-equity ratio of 0.07.
What are the recent earnings trends for Edwards Lifesciences Corporation (EW)?
Edwards Lifesciences Corporation (EW) has shown a mixed but generally positive earnings trend, recently beating analyst estimates by 5.41% in July 2026 and 6.85% in April 2026. While there was a miss in February 2026, analysts project continued earnings growth for the current and upcoming quarters.
Are insiders buying or selling EW?
Selling, on balance. In the last 18 months, EW's officers, directors and large holders reported 52 sales worth $32.6M and no open-market purchases. Grants and option exercises are not counted as buying.
What is the analyst price target for EW?
As of October 14, 2026, the 29 Wall Street analysts covering EW have 12-month targets from $84.00 to $110.00, with a median of $102.50, 18.5% above the current price of $86.47. 23 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Three months ago 22 of 29 rated it a buy.
What is EW's biggest drop in the last 10 years?
Edwards Lifesciences Corporation (EW)'s worst peak-to-trough fall over the last 10 years was -54.3%, from December 2021 to July 2024. It has not regained that peak yet and is still 33.8% below it. Over the same period, 70% of 1-year holding periods ended with a gain.
What are EW's best and worst months?
Over the last 10 years, December has been EW's strongest month on average (+4.76%, rising in 7 of 10 years) and October its weakest (-3.20%, rising in 4 of 9 years). Seasonal averages describe the past and do not predict a given year.
How closely does EW move with the stock market?
Over the past year EW's daily returns were weakly correlated with the S&P 500 (SPY) (+0.35). Nasdaq 100 (QQQ): +0.30; Bitcoin (BTC): +0.08; Gold (XAU): +0.01. A figure near +1 means the two usually move together; near 0 means little relationship.
What would $10,000 invested in EW be worth today?
$10,000 put into EW in October 2016 would be worth about $22,053 today, against about $36,506 for the same amount in the S&P 500.
